Related Experiment Video
Updated: May 13, 2026
Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction
Published on: January 12, 2016
Terazosin treatment induces caspase-3 expression in the rat ventral prostate
Georgios Papadopoulos1, Dimitrios Vlachodimitropoulos, Aspasia Kyroudi
1Department of Histology and Embryology, University of Athens Medical School, Greece.
Background:
Quinazoline-based alpha1-adrenergic receptor antagonists may not act solely on smooth muscle contractility. We evaluated the in vivo effect of terazosin on the expression of caspase-3 in the rat ventral prostate.
Methods:
Fifteen Wistar rats were treated with terazosin (1.2 mg/kg body weight, given orally every second day) for 120 days. Another 15 control animals received the same amount of distilled water. The expression of caspase-3 was assessed immunohistochemically in formalin-fixed, paraffin-embedded tissue sections.
Results:
Terazosin treatment did not affect prostate weight and histomorphology. In controls caspase-3 was expressed weakly and sporadically. In contrast, strong and weak expression was evident in 67% and 33% of the terazosin-treated specimens, respectively.
Conclusions:
These findings implicate the induction of caspase-3 expression by terazosin as a potential molecular mechanism of its apoptotic action on prostate cells.
Insights
Terazosin, an alpha1-adrenergic receptor antagonist, increases caspase-3 expression in rat prostates. This suggests terazosin may induce apoptosis in prostate cells, a key finding for understanding its cellular mechanisms.
Area of Science:
- Pharmacology
- Cell Biology
- Urology
Background:
- Quinazoline-based alpha1-adrenergic receptor antagonists may have effects beyond smooth muscle.
- Investigating the in vivo impact of terazosin on prostate cell apoptosis is crucial.
Purpose of the Study:
- To evaluate the effect of terazosin on caspase-3 expression in the rat ventral prostate.
- To explore the potential apoptotic mechanisms of terazosin in prostate tissue.
Main Methods:
- Wistar rats were treated with terazosin (1.2 mg/kg) or distilled water for 120 days.
- Immunohistochemistry was used to assess caspase-3 expression in prostate tissue sections.
Main Results:
- Terazosin did not alter prostate weight or histomorphology.
- Caspase-3 expression was significantly increased in terazosin-treated rats compared to controls.
- Strong and weak caspase-3 expression was observed in 67% and 33% of treated specimens, respectively.
Conclusions:
- Terazosin treatment induces caspase-3 expression in the rat ventral prostate.
- This induction suggests a potential molecular mechanism involving apoptosis for terazosin's action on prostate cells.
